Humana Inc. lost its second lawsuit against the Centers of Medicare & Medicaid and the Department of Health & Human Services, ...

Humana Inc. (NYSE:HUM) lost a legal battle challenging cuts to its Medicare Advantage bonus payments, raising concerns over billions in potential revenue. Per a media report on Tuesday, a Texas judge ...

A U.S. judge on Tuesday rejected Humana's bid to challenge the Centers for Medicare & Medicaid Services' 2025 ratings for its ...

Earlier this week, a Texas judge ruled against Humana in a legal challenge, upholding government-imposed downgrades to ...

Humana is a widely available Medicare Advantage provider, but star ratings have slipped from last year. Many, or all, of the products featured on this page are from our advertising partners who ...

Humana's stock took a tumble early on Wednesday after it revealed in a filing with the Securities and Exchange Commission that its Medicare Advantage star ratings had declined significantly. The ...

Humana recently reclassified Herceptin — an intravenous drug used to treat metastatic breast cancer — as a nonpreferred drug in some Florida markets, CBS12 reports. Some policyholders allege the ...

Humana's stock has fallen over 30% due to rising healthcare utilization and CMS pushing back on insurer profits, impacting MA-focused companies. Despite headwinds, Humana's Q3 earnings showed ...

The Humana Foundation, the philanthropic arm of Humana Inc. for the past 44 years, today announced its ambition, via ...

A Texas court on Tuesday struck down Humana's second lawsuit challenging Medicare Advantage star ratings released by the ...